Medizinische Universit├Ąt Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Pichler, M.
Best of ASCO 2022-bladder cancer
MEMO-MAG EUR MED ONC. 2022; Doi: 10.1007/s12254-022-00847-0
Web of Science FullText FullText_MUG

 

Leading authors Med Uni Graz
Pichler Martin
Altmetrics:

Dimensions Citations:
Plum Analytics:


Scite (citation analytics):

Abstract:
Although no game-changing studies in bladder cancer were presented this year at ASCO, we saw a series of interesting data including follow-up updates, exploratory analyses and promising results of phase I/II trials. An up-date analysis of the JAVELIN 100 Bladder study indicated a benefit of avelumab maintenance treatment irrespective of the response to platin-based first-line treatment and administration of second-line treatment. A new HER2-directed antibody drug conjugate, disitamab vedotin, showed promising results with high-response rates in HER2 high and low bladder cancer. Longer follow-up data confirmed the significant benefit of enfortumab-vedotin in the third-line treatment setting.

Find related publications in this database (Keywords)
Bladder cancer
Avelumab
Enfortumab
HER2
© Med Uni GrazImprint